Takeda Gets Positive CHMP Opinion For Recombinant ADAMTS13 In Congenital Thrombotic Thrombocytopenic Purpura
Portfolio Pulse from Benzinga Newsdesk
Takeda has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its recombinant ADAMTS13 enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP). If approved, it will be the first and only enzyme replacement therapy for cTTP in the European Union.
May 31, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda has received a positive opinion from the EMA's CHMP for its recombinant ADAMTS13 enzyme replacement therapy for cTTP. This could lead to the first approved enzyme replacement therapy for cTTP in the EU.
The positive CHMP opinion is a significant step towards approval by the European Commission. If approved, this will be the first enzyme replacement therapy for cTTP in the EU, potentially leading to increased revenue and market share for Takeda.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100